Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting In Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival For RYBREVANT
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's Phase 3 MARIPOSA-2 study for RYBREVANT has met its dual primary endpoint, showing statistically significant and clinically meaningful improvement in progression-free survival for patients with EGFR-mutated non-small cell lung cancer. This is the first Phase 3 study to show such improvement in the post-osimertinib setting and the second RYBREVANT Phase 3 study to show potential to improve outcomes in these patients.
September 06, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's RYBREVANT has shown significant potential in Phase 3 MARIPOSA-2 study, which could lead to increased demand and positive impact on the company's stock.
The positive results from the Phase 3 MARIPOSA-2 study indicate that RYBREVANT has significant potential for treating EGFR-mutated non-small cell lung cancer. This could lead to increased demand for the drug, which would likely have a positive impact on Johnson & Johnson's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100